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Abstract 
Background: Toxoplasma specific IgM antibodies; the common serologic marker 
in diagnosis of acute toxoplasmosis has its own limitations. Confirmatory testing 
with other markers, introduced as a complementary tool in distinguish acute and 
chronic infections is unusual in Iran. In the present study, we investigated the cor-
relation between the results of IgM ELISA, IgA ELISA, and IgG avidity tests in 
the diagnosis of toxoplasmosis to demonstrate the necessity of confirmatory testing 
in serodiagnosis of infection in the country.  
Methods: A total of 107 positive Toxoplasma IgG and IgM sera were obtained from 
patients referred to private laboratories and stored at -20 ºC for futures use. Sero-
logic tests were set up in duplicate to analyze the serum levels of IgG, IgM, IgA, 
and IgG avidity antibodies using commercial ELISA kits. The results were pre-
sented as semi quantitative for IgG, IgM and IgA ELISA, and Relative Avidity In-
dex in percentage for IgG avidity test. Pearson’s correlation coefficient (rp) was 
applied to analyze the data.  
Results: Of 107 serum samples, T. gondii specific IgM and IgA antibodies were 
positive in 67.3% and 53.3%, respectively. Besides, 29.9% of the sera displayed low 
avidity for IgG antibodies. The rp was - 0.572 (P<0.01) between the IgG avidity 
and IgM ELISA, - 0.364 between the IgG avidity and IgA ELISA (P<0.01), and 
0.564 between the IgM and IgA ELISA (P<0.01).  
Conclusion: The study strongly highlights the necessity of confirmatory testing in 
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Introduction 
 
oxoplasma gondii (T. gondii) is a ubiqui-
tous protozoan parasite that infects at 
least 30% of humans in most parts of 
Iran (1). Infections with T. gondii in immuno-
competent subjects are most often presented 
as asymptomatic however approximately 10 to 
20% of the acquired infections are associated 
with clinical syndromes without pathogno-
monic signs for toxoplasmosis. Moreover, the 
parasite is a main opportunistic pathogen of 
humans and life-threatening in immunocom-
promised patients. On the other hand, in pri-
mary Toxoplasma infections during pregnancy, 
the tachyzoites of T. gondii may transplacental-
ly transmit to fetus and cause severe damages 
in brain and eyes (2). The parasite can persist 
lifelong in various organs of hosts, especially 
brain and muscle, as tissue cyst (chronic infec-
tion), which is responsible for the durability of 
antibody response in chronic phase of infec-
tion, and reactivation in immunocompromised 
cases (3). 
Seroconversion from a negative to positive 
titer and a four-fold rise in antibodies titer 
over a 3-week interval are considered as the 
most reliable indicators for acute toxoplasmo-
sis (4-6). However, the former is mainly re-
stricted to monitoring program of women 
during pregnancy which is unusual in develop-
ing countries. Limitation of the latter is related 
to antibody level in serum samples of patients 
at the time of sampling which is usually at 
maximum. In spite of remarkable develop-
ment in the serology of toxoplasmosis, distin-
guishing between acute and chronic infections 
is also a main challenge in serodiagnosis of the 
disease. T. gondii specific IgM, IgA, IgE, and 
low IgG avidity antibodies, which are consid-
ered as the serologic markers for recently ac-
quired infections, have a common limitation 
that  tend to persist in chronic phase of infec-
tion (7-12).  
An IgG avidity test has been widely used to 
differentiate between the recent and latent in-
fections of T. gondii, especially during preg-
nancy (13 -23). In this test, a high avidity in-
dex can certainly exclude the occurrence of 
infection within recent 3 to 5 months and 
therefore it is considered as a reliable indicator 
to rule out acquired infection during preg-
nancy during the first trimester (15). However, 
a low avidity index which regards the infection 
as acquired recently may persist for more than 
one year and thus cannot be used as a definite 
marker for recent infections with Toxoplasma 
(17, 21). Protracted low avidity of IgG anti-
bodies that is attributed to delayed maturation 
of IgG avidity antibodies (17) may affect the 
anti-Toxoplasma therapy in pregnant women 
(24). A high IgG avidity is considered as a sin-
gle reliable marker to exclude the acquired in-
fections during pregnancy in women who are 
tested within the first trimester (14-16, 19-21).  
In view of the limitations propounded for 
each of the serological markers in differentiat-
ing the recent and past infections of T. gondii, 
the complementary testing is considered as a 
tool for increasing the accuracy in the detec-
tion of clinical toxoplasmosis or to determine 
primary infections during pregnancy (10-21). 
In USA, a panel of serological tests may be 
used to confirm Toxoplasma IgM positive sam-
ples in a serology reference laboratory (25), 
whereas in Iran, the simultaneous measure-
ment of IgG and IgM antibodies in a single 
serum is the only criterion for judging and 
making a decision over toxoplasmosis. In a 
report from Iran, only 18 serum samples with 
positive results for IgM antibodies to T. gondii 
were evaluated with IgG avidity test (26), a 
sample size insufficient to show an im-
portance for complementary tests in diagnosis 
of toxoplasmosis in the country. The present 
study was performed to clarify the necessity 
for confirmatory testing in serodiagnosis of 
toxoplasmosis in Iran. To achieve the objec-
tive of the study, the authors evaluated IgA 
ELISA and IgG avidity as confirmatory tests 
T 
Iranian J Parasitol: Vol. 8, No. 4, Oct -Dec 2013, pp.608-616 
 
610                                                                                             Available at: http://ijpa.tums.ac.ir                                                                                                     
in diagnosis of recently acquired infections of 
T. gondii in specimens with positive results for 
IgM antibodies to T. gondii.   
 
Material and Methods 
 
Serum samples 
A total of 131 serum samples were collected 
from patients suspected of having toxoplasmo-
sis and referred to 3 private laboratories in 
Tehran and Qazvin Province, located 150 km 
northwest of Tehran, during 2011 to 2012. The 
sera were unknown in the existing clinical set-
tings and stored at -20 °C until use. Initially, all 
serum samples were examined for anti-T. gondii 
IgG antibodies by enzyme-linked immuno-
sorbent assay (ELISA) in reference lab and 
those negative for antibody, excluded from the 
study. Of 131 serum samples, 107 were found 
positive in the initial screening of specimen and 
thus used for the measurement of T. gondii IgM, 
IgA, and IgG avidity antibodies. 
 
IgG, IgM, and IgA ELISA 
Anti-T. gondii IgG, IgM, and IgA antibodies 
were detected by commercial kits (Euroim-
mun, Germany). The tests were performed 
according to the manufacturer’s instructions. 
All samples were tested in duplicate. The opti-
cal density (OD) of wells was measured in a 
microplate reader (Awareness, Stat Fax 3200, 
USA) at 450 nm while a wavelength of 620 
nm was used as reference. The results were 
expressed semi-quantitatively by calculating 
the ratio of the extinction value of the control 
or patient sample over the extinction value of 
calibrator and considered positive for ra-
tio≥1.1, negative<0.8, and borderline≥0.8 - 
<1.1 for all three classes of antibodies.  
 
IgG Avidity ELISA Test 
Avidity determination of IgG antibodies 
against T. gondii was conducted by ELISA 
method using commercial kits (Euroimmun, 
Germany). Serum samples were examined ac-
cording to the manufacturer’s instructions. 
The results obtained were presented by calcu-
lating the percentage of relative avidity index 
(RAI %) of the extinction of sample treated 
with urea over the extinction of sample with-
out urea treatment. A RAI of <40% was in-
dicative of low antibodies; a RAI of >60% 
indicated the presence of high avidity antibod-




Data were analyzed using SPSS version 13 
statistical package. The descriptive results 
were presented as mean± SD (standard devia-
tion). Also, Kappa coefficient, Pearson’s cor-
relation coefficient (rp) and regression were 





Of 107 serum samples from patients sus-
pected of having  toxoplasmosis, specific IgM 
and IgA antibodies to T. gondii were positive in 
67.3% (n=72) and 53.3% (n=57), respectively. 
Similarly, 29.9% (n=32) of the sera displayed 
low avidity for IgG antibodies. The minimum, 
maximum, and mean±SD of ratio indexes for 
positive sera were 1.20, 8.56, and 4.47±1.64 
for IgG antibodies; 1.10, 9.12, and 2.65±1.70 
for IgM antibodies, and 1.10, 6.82; and 
2.83±1.52 for IgA antibodies, respectively. In 
addition, the minimum, maximum, and 
mean±SD of RAI% for sera with low avidity 
were 6.9, 38.2, and 20.4±7.89, respectively.    
In 24.3% (n=26) of serum samples, both 
IgM and IgA antibodies were positive while 
the avidity index showed low reaction for IgG 
antibodies. On the other hand, 14% (n=15) of 
the sera were negative for both IgM and IgA 
antibodies, demonstrating a high avidity reac-
tion for the IgG avidity (Table 1). 
Pearson’s correlation coefficient (rp) be-
tween the RAI% of IgG avidity and the ratio 
index of IgM was -0.572 (P<0.01) and the 
equation of regression line was drawn as {IgG 
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avidity= 70.16-8.2 × (IgM ratio)}, i.e. it is ex-
pected that one unit increase in IgM ratio to 
be accompanied with reduction of RAI% by 
8.2 units (Fig. 1). 
 
Table 1: Comparison of IgM ELISA, IgA ELISA, and IgG avidity tests for diagnosis of toxoplasmosis in 107 
patients suspected of having toxoplasmosis 
 
IgG avidity IgA-ELISA IgM-ELISA 
Borderline High Low   
9 16 26 Positive Positive 
4 9 3 Negative  
1 3 1 Borderline  
0 2 ND* Positive Negative 
3 15 ND Negative  
0 1 ND Borderline  
0 3 1 Positive Borderline 
1 6 0 Negative  
0 2 1 Borderline  
18 57 32 Total 
*ND: not done 
 
The rp was calculated at -0.364 between the 
indexes of IgG avidity and IgA (P<0.01) with 
the equation of regression line drawn as {IgG 
avidity= 63.18 – 5.43× (IgA ratio)}. Also, the 
rp between the IgM ratio and IgA ratio was 
0.564 (P<0.01), and the equation of regression 
line drawn as {IgM ratio= 0.98 + 0.59 × (IgA 




Fig. 1: Scatter diagram and regression line for IgM 
and IgG avidity antibodies to T. gondii in 107 pa-
tients suspected of having toxoplasmosis  
The results of IgM ELISA and IgG avidity 
were completely in agreement with the find-
ings obtained for 45.8% (n=49) of  samples. 
Of 72 specimens with positive IgM ELISA 
results, 41.6% (n=30) demonstrated low IgG 
avidity whereas among those with negative 
IgM ELISA results (n=21), 85.7% (n=18) 




Fig 2: Scatter diagram and regression line for IgA 
and IgG avidity antibodies to T. gondii in 107 pa-
tients suspected of having toxoplasmosis 
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On the other hand, none of the 21 samples 
with negative results for IgM did not show 
low avidity reaction (Table 2). Kappa coeffi-
cient between the results of two tests was 
0.192.   
 
Table 2: Comparison of IgM ELISA and IgG 
avidity tests for diagnosis of toxoplasmosis in 107 




Borderline Negative Positive  
2 0 30 Low 
11 18 28 High 
1 3 14 Borderline 
14 21 72 Total 
 
The results of IgA ELISA and IgG avidity 
showed a full agreement in 54.2% (n=58) of 
cases. In other words, 47.4% (n=27) out of 57 
specimens with positive results for IgA ELISA, 
showed low IgG avidity whereas a high level 
IgG avidity was found in 73.2% (n=30) out of 
41 serum samples whose results for IgA ELI-
SA were negative. However, 7.3% (n=3) of 
samples with negative results for IgA anti-
bodies displayed low avidity (Table 3). Kappa 
coefficient between the results of two tests 
was calculated at 0.264.    
 
Table 3: Comparison of IgA ELISA and IgG 
avidity tests for diagnosis of toxoplasmosis in 107 
patients suspected of having toxoplasmosis 
 
IgA-ELISA IgG avidity 
Borderline Negative Positive  
2 3 27 Low 
6 30 21 High 
1 8 9 Borderline 
9 41 57 Total 
 
The highest agreement was observed be-
tween the results of IgM and IgA ELISA, i.e., 
66.4% (n=71) of 107 cases demonstrated simi-
lar patterns. Of 72 serum samples positive for 
IgM ELISA, 69.4% (n=50) also showed posi-
tive results for IgA ELISA. Of 57 samples 
with positive results for IgA ELISA, 87.7% 
(n=50) also found to be positive for IgM 
ELISA. Moreover, 85.7% (n=18) of the 21 
specimens whose IgM ELISA were negative, 
had similar results for IgA ELISA. Of 41 sam-
ples with negative results for IgA antibodies, 
43.9% (n=18) showed negative results for IgM 
ELISA. Kappa coefficient between the results 
of IgM and IgA ELISA was 0.406. 
Of 72 specimens positive for IgM to T. 
gondii, the ratio indexes were 1.1-2 in 32.7% 
(n=35), 2-4 in 23.4% (n=25), and > 4 in 
11.2% (n=12) cases. Of 35 samples with ratio 
indexes of 1.1-2, 17.1% (n=6) demonstrated 
low avidity reaction whereas the reaction rate 
of 83.3% (n=10) from 12 samples with IgM 
ratio indexes > 4 showed low avidity for IgG 
antibodies. On the other hand, of 57 serum 
samples with positive results for IgA ELISA, 
the ratio indexes were 1.1-2 in 42.1 (n=24), 2-
4 in 35.1% (n=20), and > 4 in 22.8% (n=13) 
cases. Of 24 samples with IgA ratio indexes of 
1.1-2, 33.3% (n=8) had low avidity reaction 
whereas the avidity reaction of 61.5% (n=8) 
from 13 samples with IgA ratio indexes > 4, 
was low. 
 
Table 4: Comparison of IgA ELISA and IgM 
ELISA for diagnosis of toxoplasmosis in 107 pa-




Borderline Negative Positive  
5 17 50 Positive 
1 18 2 Negative 
3 6 5 Borderline 




In the present study, there was a remarkable 
difference between IgA ELISA and IgG avid-
ity tests in confirming the specimens with pos-
itive IgM antibodies against T. gondii. In other 
words, almost 70% of IgM positive samples 
were confirmed by IgA whereas nearly 40% of 
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the specimens showed low avidity for IgG 
antibodies. Higher frequency of positive sam-
ples for IgM and IgA antibodies in compari-
son with low avidity for IgG antibodies has 
been also shown in other studies (7, 10), a 
finding probably due to difference in durabil-
ity of the antibodies in chronic phase (10) and 
diversity in sensitivity of the assays (18).  In a 
study by Kodym et al., Toxoplasma IgM and 
IgA antibodies remained positive for 12-18, 
and 6-9 months, respectively (10), and Auer et 
al. reported a higher sensitivity for IgM ELI-
SA compared with IgA ELISA (18).  Hence, it 
seems that the measurement of IgM antibod-
ies has superiority to other serological markers 
for the initial diagnosis of T. gondii infections. 
Our findings support other studies that em-
phasize on confirmatory testing in serodiag-
nosis of toxoplasmosis (4-6,15, 16, 18, 19, 21), 
however, the interpretation of the test results 
is difficult in some cases. At present, there is 
no unique serological pattern for confirming 
toxoplasmosis. The limitations of serological 
tests and their interpretive problems in distin-
guishing between acute and latent infections 
require the primary results to be confirmed in 
a reference laboratory. At Toxoplasma Serology 
Laboratory in Palo Alto Medical Foundation, 
known as the reference laboratory for the U.S. 
Centers for Disease Control and Prevention 
(CDC) and Food and Drug Administration 
(FDA), a battery of tests as Toxoplasma serolo-
gy profile (TSP) is used which is slightly dif-
ferent in clinical settings. The TSP has been 
demonstrated to be a useful tool to distinguish 
between acute and chronic infections (2).  
We showed a significant association between 
increasing the IgM and IgA antibodies indexes 
and decreasing the avidity index for IgG anti-
bodies, a finding in agreement with the results 
of previous studies (16, 21, 27, 28). In our 
study, a low avidity was demonstrated in 
83.3% (10/12) and 61.5% (8/13) of samples 
with index > 4 for IgM and IgA antibodies, 
respectively. It seems that a high IgM antibody 
index is a more reliable marker than a high 
IgA antibody index in confirming acute toxo-
plasmosis. However, our results cannot argue 
with certainty which of the IgA ELISA and 
IgG avidity tests is more appropriate to con-
form the positive samples for IgM to T. gondii. 
To answer this question, serum samples of 
known history and clinical setting is required 
which was a main limitation of the present 
study. 
Considering high avidity as an indicator to 
rule out recent infections in samples with pos-
itive results for IgM antibodies to T. gondii, 
38.9% of 72 IgM positive samples in our study 
may have been implicated in latent infections. 
However, a high avidity for IgG antibodies 
cannot be regarded as a definite criterion for 
excluding acute toxoplasmosis in individuals 
who are positive for IgM antibody to the para-
site. For example, lymphadenitis due to T. 
gondii may sustain for more than 6 months, 
whereas, the avidity index of IgG antibodies 
may convert from low to high prior to the 
time when the swollen lymph nodes in the 
disease subside (11, 19, 30). Also, the results 
of high IgG avidity test can be misleading in 
patients with ocular toxoplasmosis caused by 
reactivation of T. gondii (31).  
The frequency of a high IgG avidity in se-
rum samples containing specific T. gondii IgM 
antibodies has been diverse in different studies, 
for example, 66.3% (18), 51.9% (21), 48.7% 
(15), 56% (32), and 61.3% (20). These differ-
ences have been attributed to several possible 
factors, including; heterogeneity in clinical set-
ting of toxoplasmosis, heterogeneity in popu-
lation, function of immune system at time of 
blood collection, interval between sampling 
time and beginning of infection, lack of stand-
ardization of serological tests, diversity in anti-
gen preparation, anti-Toxoplasma therapy, and 
variations in calculating the avidity index (33).  
In Iran, a developing country located in 
western Asia, where at least 30% of the popu-
lations, widely scattered in many parts of the 
country, are seropositive for T. gondii (34, 35), 
and the diagnosis of toxoplasmosis is facing 
two main challenges. Firstly, clinicians may be 
unaware of serodiagnostic problems of the 
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parasitic infection. Secondly, there is not a ref-
erence center for confirmatory testing of the 
disease in the country. Therefore, management 
of patients suspected of having toxoplasmosis 
and making a decision about pregnant women 
who are screened for congenital toxoplasmosis 
may lead to unnecessary interventions with an-
ti-toxoplasma drugs which are mostly with ad-




The results of our study highlight a necessity 
for confirmatory testing in diagnosis of toxo-
plasmosis in Iran. We recommend the Toxo-
plasma serology laboratory to be established 
within the university reference centers in all 
provinces of the country while being super-
vised by a specialist in parasitology. Also, 
training courses for clinicians will help en-
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